Army Marshals Resources To Aid In Race For Coronavirus Vaccine

Enlarge this image

A research assistant with the Emerging Infectious Disease Branch (EIDB), at the Walter Reed Army Institute of Research (WRAIR), studies coronavirus protein samples, June 1, 2020. The EIDB is part of WRAIR’s effort to produce a COVID-19 vaccine candidate.

Mike Walters/U.S. Army

hide caption

toggle caption

Mike Walters/U.S. Army

Coronavirus Live Updates
States Prepare For Potential Fall Vaccine Distribution Under Pressure From CDC

The idea is that the immune system would get to know this protein — through the vaccine — and when the real virus hits, the immune system would know how to fight it.

Hajduczki became fascinated with viruses as a young girl in Hungary, watching her pathologist mother work on AIDS victims back in the early 1980s.

«So even, you know, when the world didn’t necessarily know about that this virus is happening like that was our dinner table conversation,» she says.

Now she has a young daughter, and has brought her to the lab during this pandemic, because like many parents around the country, Hajduczki and her husband are scrambling between work and childcare duties. Her voice breaks when she talks about the effect the virus is having on her work and family life.

Enlarge this image

Agi Hajduczki is a research scientist at the Walter Reed Army Institute of Infectious Diseases. She is part of a team working on a COVID-19 vaccine.

Tom Bowman/NPR

hide caption

toggle caption

Tom Bowman/NPR

Modjarrad says he knew he was interested in medicine early on, «I got my first Fisher-Price doctor’s kit when I was four for the Persian New Year.»

Modjarrad is developing the Army’s coronavirus vaccines, but is also part of Operation Warp Speed, the government’s efforts to help private companies in the U.S. and internationally create coronavirus vaccines.

«So our institution and our network of sites here in the US and internationally are involved with many different companies,» he says.

That means sharing the Army’s expertise. Labs. Research animals. Locations for human trials, in Washington, D.C., San Diego and San Antonio. The Army also has partners and labs in Europe, Asia and Africa.

Modjarrad and other officials liken the vaccine effort to a horse race, with multiple companies coming out of the gate at the same time.

«Sort of whole of government approach has been putting our bets on multiple horses because we’re not interested in one particular horse,» he says. «We’re interested in a horse, at least one horse, making it across the finish line as fast as possible and being safe and effective and accessible for our entire public and population.»

Right now, several companies are working on the final phase three of human trials in developing a vaccine.

«It’s not like after the Phase three trial, ‘Hey, the vaccine is ready for everyone,'» Modjarrad says. «We start to phase it into the population and we still collect information on how people are responding to that vaccine until we get to a point where it becomes broadly available to the entire population.»

Enlarge this image

Kayvon Modjarrad is the scientist heading Army efforts to aid in the race for a vaccine for the current pandemic.

Samir Deshpande/Walter Reed Army Institute of Infectious Diseases

hide caption

toggle caption

Samir Deshpande/Walter Reed Army Institute of Infectious Diseases

Coronavirus Live Updates
9 Drugmakers Sign Safety Pledge In Rush To Develop Coronavirus Vaccine

«There’s been a lot of concern about what’s being sacrificed by moving so quickly,» he acknowledges. «And I can tell you, one thing is very clear it’s being sacrificed and it’s money.»

Michael says in the past vaccine development would take so long — often years — in part because companies and governments were wary of making an investment. A vaccine would be manufactured only after all approvals were done. The coronavirus changed all that.

«Now, everyone’s throwing financial caution to the winds and billions of dollars are in play,» Michael says. «But now you have, of course, a worldwide pandemic that’s costing trillions of dollars and impacting, you know, millions of people’s lives.»

Michael is also concerned about another controversy: Are human trials getting to a good cross section of the population, especially by race?

«If you look at the impact of the SARS-CoV-2 infection and the disease it causes, COVID-19, there is a disproportional impact on people of color in the United States,» he says. «So you are at much greater risk if you’re over 65, if you have comorbidities, hypertension, obesity.»

Many of the comorbidities that are particularly present in minority segments of society.

«Blacks and Latin and Native populations in our country are at substantially higher risk,» he says. «So it’s more important than ever that we have diversity and inclusion in these studies.»

All those working on the vaccine, whether private or government efforts «want to do better. I can tell you that.»

Enlarge this image

Nelson Michael, director of the Center for Infectious Disease Research, says a strong public health campaign will be needed to convince Americans the vaccine is safe and effective.

Tom Bowman/NPR

hide caption

toggle caption

Tom Bowman/NPR

Nelson Michael, director of the Center for Infectious Disease Research, says a strong public health campaign will be needed to convince Americans the vaccine is safe and effective.

Tom Bowman/NPR

Michael acknowledges the suspicions especially in the Black community, who have been victims of government studies. The most horrific was the Tuskegee Experiment, which from the 1930s in the 1970s followed hundreds of Black men with syphilis over the course of their lives, failing to tell them about the diagnosis and refusing to treat them.

For this vaccine, says Michael, the government has created community engagement groups to reach out to African American and Native Americans in particular.

«I’d say Native populations are also very mistrustful because of the history,» Michael adds. «And you know there are lots of issues, of course, that are hitting our country right now all at the same time, systemic racism.»

But he says there likely to be an even greater challenge once a vaccine is approved.

«I am more concerned about how we’re going to execute a vaccine campaign than I am about how we’re going to test this vaccine,» he says. «How are we going to convince Americans that they should sign up for their vaccine?»

Some polls show at least 30% of Americans say they won’t take the vaccine. There are scientists who say at least 40% of Americans must take the vaccine. Michael puts that percentage even higher.

«What we really need is to have somewhere between 70% and 90% of Americans that either have been vaccinated and have immunity that way or have been exposed and survived and have immunity because of natural infection,» he says.

A vaccine from at least one of the private companies is expected earlier next year. The Army also continues to work on its own vaccine that can target future coronaviruses.

No matter what, a strong public health campaign will be needed, Michael says, to convince Americans the vaccine is safe and effective. One part of that is to reach out to those people Americans tend to trust most: Their family doctor.

• operation warp speed
• vaccine
• Walter Reed
• Army